Search

Your search keyword '"Avumegah M"' showing total 6 results
Start Over Author "Avumegah M"
6 results on '"Avumegah M"'

1. Molecular clamp stabilised Spike protein for protection against SARS-CoV-2

Author

Watterson, D, Wijesundara, D, Modhiran, N, Mordant, F, Li, Z, Avumegah, M, McMillan, C, Lackenby, J, Guilfoyle, K, Amerongen, GV, Stittelaar, K, Cheung, S, Bibby, S, Daleris, M, Hoger, K, Gillard, M, Radunz, E, Jones, M, Hughes, K, Hughes, B, Goh, J, Edwards, D, Scoble, J, Pearce, L, Kowalczyk, L, Phan, T, La, M, Lu, L, Pham, T, Zhou, Q, Brockman, D, Morgan, S, Lau, C, Tran, M, Tapley, P, Letelier, FV, Barnes, J, Young, A, Jaberolansar, N, Scott, C, Isaacs, A, Amarilla, A, Khromykh, A, Reading, P, Ranasinghe, C, Subbarao, K, Munro, T, Young, P, Chappell, K, Watterson, D, Wijesundara, D, Modhiran, N, Mordant, F, Li, Z, Avumegah, M, McMillan, C, Lackenby, J, Guilfoyle, K, Amerongen, GV, Stittelaar, K, Cheung, S, Bibby, S, Daleris, M, Hoger, K, Gillard, M, Radunz, E, Jones, M, Hughes, K, Hughes, B, Goh, J, Edwards, D, Scoble, J, Pearce, L, Kowalczyk, L, Phan, T, La, M, Lu, L, Pham, T, Zhou, Q, Brockman, D, Morgan, S, Lau, C, Tran, M, Tapley, P, Letelier, FV, Barnes, J, Young, A, Jaberolansar, N, Scott, C, Isaacs, A, Amarilla, A, Khromykh, A, Reading, P, Ranasinghe, C, Subbarao, K, Munro, T, Young, P, and Chappell, K

Abstract

Efforts to develop and deploy effective vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continue at pace with more than 30 candidate vaccines now in clinical evaluation. Here we describe the preclinical development of an adjuvanted, prefusion-stabilised Spike (S) protein “Sclamp” subunit vaccine, from rational antigen design through to assessing manufacturability and vaccine efficacy. In mice, the vaccine candidate elicits high levels of neutralising antibodies to epitopes both within and outside the receptor binding domain (RBD) of S, as well as broadly reactive and polyfunctional S-specific CD4+ and cytotoxic CD8+ T cells. We also show protection in Syrian hamsters, which has emerged as a robust animal model for pulmonary SARS-CoV-2 infection. No evidence of vaccine enhanced disease was observed in animal challenge studies and pre-clinical safety was further demonstrated in a GLP toxicology study in rats. The Sclamp vaccine candidate is currently progressing rapidly through clinical evaluation in parallel with large-scale manufacture for pivotal efficacy trials and potential widespread distribution.

Published
2020

2. The changing epidemiology worldwide of Mycobacterium ulcerans

Author

O'Brien, DP, Jeanne, I, Blasdell, K, Avumegah, M, Athan, E, O'Brien, DP, Jeanne, I, Blasdell, K, Avumegah, M, and Athan, E

Abstract

Mycobacterium ulcerans is recognised as the third most common mycobacterial infection worldwide. It causes necrotising infections of skin and soft tissue and is classified as a neglected tropical disease by the World Health Organization (WHO). However, despite extensive research, the environmental reservoir of the organism and mode of transmission of the infection to humans remain unknown. This limits the ability to design and implement public health interventions to effectively and consistently prevent the spread and reduce the incidence of this disease. In recent years, the epidemiology of the disease has changed. In most endemic regions of the world, the number of cases reported to the WHO are reducing, with a 64% reduction in cases reported worldwide in the last 9 years. Conversely, in a smaller number of countries including Australia and Nigeria, reported cases are increasing at a rapid rate, new endemic areas continue to appear, and in Australia cases are becoming more severe. The reasons for this changing epidemiology are unknown. We review the epidemiology of M. ulcerans disease worldwide, and document recent changes. We also outline and discuss the current state of knowledge on the ecology of M. ulcerans, possible transmission mechanisms to humans and what may be enabling the spread of M. ulcerans into new endemic areas.

Published
2019

5. The changing epidemiology worldwide of .

Author

O'Brien, D. P., Jeanne, I., Blasdell, K., Avumegah, M., and Athan, E.

Abstract

Mycobacterium ulcerans is recognised as the third most common mycobacterial infection worldwide. It causes necrotising infections of skin and soft tissue and is classified as a neglected tropical disease by the World Health Organization (WHO). However, despite extensive research, the environmental reservoir of the organism and mode of transmission of the infection to humans remain unknown. This limits the ability to design and implement public health interventions to effectively and consistently prevent the spread and reduce the incidence of this disease. In recent years, the epidemiology of the disease has changed. In most endemic regions of the world, the number of cases reported to the WHO are reducing, with a 64% reduction in cases reported worldwide in the last 9 years. Conversely, in a smaller number of countries including Australia and Nigeria, reported cases are increasing at a rapid rate, new endemic areas continue to appear, and in Australia cases are becoming more severe. The reasons for this changing epidemiology are unknown. We review the epidemiology of M. ulcerans disease worldwide, and document recent changes. We also outline and discuss the current state of knowledge on the ecology of M. ulcerans, possible transmission mechanisms to humans and what may be enabling the spread of M. ulcerans into new endemic areas. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

6. The changing epidemiology worldwide of Mycobacterium ulcerans .

Author

O'Brien DP, Jeanne I, Blasdell K, Avumegah M, and Athan E

Abstract

Mycobacterium ulcerans is recognised as the third most common mycobacterial infection worldwide. It causes necrotising infections of skin and soft tissue and is classified as a neglected tropical disease by the World Health Organization (WHO). However, despite extensive research, the environmental reservoir of the organism and mode of transmission of the infection to humans remain unknown. This limits the ability to design and implement public health interventions to effectively and consistently prevent the spread and reduce the incidence of this disease. In recent years, the epidemiology of the disease has changed. In most endemic regions of the world, the number of cases reported to the WHO are reducing, with a 64% reduction in cases reported worldwide in the last 9 years. Conversely, in a smaller number of countries including Australia and Nigeria, reported cases are increasing at a rapid rate, new endemic areas continue to appear, and in Australia cases are becoming more severe. The reasons for this changing epidemiology are unknown. We review the epidemiology of M. ulcerans disease worldwide, and document recent changes. We also outline and discuss the current state of knowledge on the ecology of M. ulcerans, possible transmission mechanisms to humans and what may be enabling the spread of M. ulcerans into new endemic areas.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results